Results 211 to 220 of about 310,372 (257)

Supplemental glucose oxidase as an antibiotic substitute alleviates diarrhea and improves intestinal health in weaned piglets. [PDF]

Vet Q
Chen D, Chen J, Dong Z, Cao Q, Ye H, Feng D, Zhang C, Zuo J, Wang W.   +8 more
europepmc   +1 more source

Anti‐Obesity Pharmacotherapy and Emerging Multimodal Interventions for Obstructive Sleep Apnea

Chronic Diseases and Translational Medicine, EarlyView.
Cellular and molecular mechanisms of obesity‐related obstructive sleep apnea (OSA). ADMA: asymmetric dimethyrarginine, NLRP3: nucleotide‐binding domain, leucine‐rich repeat family, Pyrin domain containing 3, TLR: toll‐like receptors, IL‐1β: interleukin‐1β, IL‐6: interleukin‐6; LPS: lipopolysacharide, ROS: reactive oxygen species, TNF‐α.
Anish Preshy, Cornelius J. Fernandez, Mohammad Hamid Nedai, Joseph M. Pappachan   +3 more
wiley   +1 more source

Glucose oxidase: An emerging multidimensional treatment option for diabetic wound healing. [PDF]

Bioact Mater
Liao Y, Zhang Z, Zhao Y, Zhang S, Zha K, Ouyang L, Hu W, Zhou W, Sun Y, Liu G.   +9 more
europepmc   +1 more source

Living Microbial Drugs

Chemistry – A European Journal, EarlyView.
The introduction outlines the review scope. Microbial cell factories as living drugs cover host–gut microbiota, bacteria, yeast, and other microbial systems, with comparative host advantages. Engineering strategies include synthetic circuits, quorum sensing, and memory.
Cemile Elif Özçelik, Nazlıcan Tunç, Senem Şen, Urartu Özgür Şafak Şeker   +3 more
wiley   +1 more source

Synergistic Enzybiotic Effect of a Bacteriophage Endolysin and an Engineered Glucose Oxidase Against <i>Listeria</i>. [PDF]

Biomolecules
Talens-Perales D, Daròs JA, Polaina J, Marín-Navarro J.   +3 more
europepmc   +1 more source

Engineering and Characterization of a Fluorescent Fission Yeast Arp2/3 Complex for Single Molecule Mechanistic Investigations

Cytoskeleton, EarlyView.
ABSTRACT Arp2/3 complex is a seven‐component protein complex that facilitates the assembly of branched actin filament networks by binding to pre‐existing “mother” actin filaments and initiating the nucleation of new branched “daughter” filaments. Arp2/3 complex must be activated by a nucleation promoting factor such as the WASP/Scar protein family. The
Caitlin A. Anderson, Meghan E. O'Connell, Kaitlin E. Homa, Cristian Suarez, Michael L. James, Kashmeera D. Baboolall, Vilmos Zsolnay, Vladimir Sirotkin, David R. Kovar   +8 more
wiley   +1 more source

The gas|liquid interface eclipses the liquid|liquid interface for glucose oxidase rate acceleration in microdroplets. [PDF]

Proc Natl Acad Sci U S A
Krushinski LE, Herchenbach PJ, Dick JE.
europepmc   +1 more source

Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review

Clinical Pharmacology &Therapeutics, EarlyView.
Interest in ayahuasca and its main component, N,N‐Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited.
Tijana Stojanović, Kent W. Nilsson, Robert Fredriksson, Helgi B. Schiöth, Thiago C. Moulin   +4 more
wiley   +1 more source

Safety evaluation of the food enzyme glucose oxidase from the non-genetically modified <i>Aspergillus tubingensis</i> strain GOX. [PDF]

EFSA J
EFSA Panel on Food Enzymes (FEZ), Zorn H, Barat Baviera JM, Bolognesi C, Catania F, Gadermaier G, Greiner R, Mayo B, Mortensen A, Roos YH, Solano MLM, Sramkova M, Van Loveren H, Vernis L, Aguilera J, Andryszkiewicz M, Pesce F, Marini E, Criado A, Liu Y.   +19 more
europepmc   +1 more source

A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders

Clinical Pharmacology &Therapeutics, EarlyView.
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease‐modifying therapies that have been evaluated in ...
Pepijn P.N.M. Eijsvogel, Lars M.G. Smits, Philip H.C. Kremer, Geert Jan Groeneveld   +3 more
wiley   +1 more source